Retinal pigment epithelium (RPE)–choroid graft translocation in the treatment of an RPE tear: preliminary results
- 1Department of Vitreoretinal Surgery, the Rotterdam Eye Hospital, Rotterdam, The Netherlands
- 2Department of Ophthalmology, University of Düsseldorf, Düsseldorf, Germany
- 3Department of Vitreoretinal Surgery, Center of Ophthalmology, University of Cologne, Cologne, Germany
- 4Erasmus University Rotterdam, Rotterdam, The Netherlands
- Dr K Maaijwee, The Rotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands; kmaaijwee{at}hotmail.com
- Accepted 15 November 2007
Abstract
Aim: To investigate whether retinal pigment epithelium (RPE)–choroid translocation would be a suitable treatment for RPE tears, which have a poor prognosis and are encountered more often since the introduction of anti-(vascular endothelial growth factor (VEGF)) therapy for exudative age-related macular degeneration (AMD).
Methods: Prospective interventional case series of six eyes of six patients with AMD with an RPE tear treated with an RPE–choroid translocation. The RPE tear occurred in a vascularised pigment epithelium detachment in four patients and after treatment in the other two. Preoperative and postoperative evaluation included ETDRS visual acuity (VA) and fixation testing. The follow-up period ranged from 6 months to 2 years.
Results: The mean preoperative VA was 20/160 (range 20/400–20/80). The mean VA at the last examination after surgery was 20/80 (range 1/60–20/50). One of the six patients had a preoperative VA of ≥20/80, and four had a VA of 20/80 or better at their last examination. Foveal fixation on the graft was present in five of the six eyes up to the last examination.
Conclusion: These preliminary data show that an RPE–choroid translocation may be a treatment option for patients with an RPE tear.
Footnotes
-
Funding: This study was supported by the SWOO-Flieringa Foundation (Foundation Scientific Research Eye Hospital Rotterdam), the Rotterdam Eye Hospital, Rotterdam, The Netherlands.
-
Competing interests: None.
-
Ethics approval: Ethics approval was obtained.
-
Patient consent: Patient consent was obtained for publication of figs 1 and 2.







